Overview
- Pfizer's dividend yield is about 6.6% versus Eli Lilly's roughly 0.6%, a gap driven mainly by Pfizer's lower share price rather than a stronger cash payout from the company.
- Eli Lilly's recent performance is powered by GLP‑1 drugs: Mounjaro and Zepbound posted roughly 125% and 80% sales growth in Q1 2026, helping lift Lilly's revenue and sending its stock sharply higher over the past five years.
- Pfizer's shares have lagged, reflecting weaker post‑pandemic COVID vaccine sales and market concern about upcoming patent expirations for key drugs such as Ibrance in 2027 and Eliquis and Vyndaqel the following year.
- After halting its own GLP‑1 research in 2025, Pfizer acquired a company with a newer GLP‑1 candidate and continues to run about 20 major studies in 2026 as it tries to rebuild growth prospects.
- For investors the choice is clear: prioritize capital growth tied to GLP‑1 expansion at Lilly or seek current income from Pfizer's high yield, with the key risks to watch being GLP‑1 competition, patent cliffs, and the companies' pipelines.